Compare CCCC & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | NATH |
|---|---|---|
| Founded | 2015 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 418.8M |
| IPO Year | 2020 | 1996 |
| Metric | CCCC | NATH |
|---|---|---|
| Price | $4.25 | $100.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 14.0K |
| Earning Date | 05-06-2026 | 06-09-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ 4.85 |
| Revenue | $35,947,000.00 | ★ $104,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.82 |
| Revenue Growth | 1.02 | ★ 7.81 |
| 52 Week Low | $1.40 | $88.67 |
| 52 Week High | $4.60 | $117.49 |
| Indicator | CCCC | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 44.27 |
| Support Level | $2.10 | $100.26 |
| Resistance Level | $4.60 | $101.76 |
| Average True Range (ATR) | 0.36 | 0.73 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 72.60 | 3.60 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.